218 related articles for article (PubMed ID: 19637311)
1. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly.
Theodoropoulou M; Tichomirowa MA; Sievers C; Yassouridis A; Arzberger T; Hougrand O; Deprez M; Daly AF; Petrossians P; Pagotto U; Beckers A; Stalla GK
Int J Cancer; 2009 Nov; 125(9):2122-6. PubMed ID: 19637311
[TBL] [Abstract][Full Text] [Related]
2. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
3. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
4. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
[TBL] [Abstract][Full Text] [Related]
5. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
Colao A; Pivonello R; Auriemma RS; Briganti F; Galdiero M; Tortora F; Caranci F; Cirillo S; Lombardi G
J Clin Endocrinol Metab; 2006 Jun; 91(6):2112-8. PubMed ID: 16537687
[TBL] [Abstract][Full Text] [Related]
6. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
[TBL] [Abstract][Full Text] [Related]
7. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and limits of somatostatin analogs.
Petersenn S
J Endocrinol Invest; 2005; 28(11 Suppl International):53-7. PubMed ID: 16625846
[TBL] [Abstract][Full Text] [Related]
9. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
Resmini E; Dadati P; Ravetti JL; Zona G; Spaziante R; Saveanu A; Jaquet P; Culler MD; Bianchi F; Rebora A; Minuto F; Ferone D
J Clin Endocrinol Metab; 2007 May; 92(5):1592-9. PubMed ID: 17311860
[TBL] [Abstract][Full Text] [Related]
10. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
11. Long-term primary medical therapy with somatostatin analogs in acromegaly.
Su DH; Liao KM; Chen HW; Chang TC
J Formos Med Assoc; 2006 Aug; 105(8):664-9. PubMed ID: 16935768
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
Chahal HS; Trivellin G; Leontiou CA; Alband N; Fowkes RC; Tahir A; Igreja SC; Chapple JP; Jordan S; Lupp A; Schulz S; Ansorge O; Karavitaki N; Carlsen E; Wass JA; Grossman AB; Korbonits M
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1411-20. PubMed ID: 22659247
[TBL] [Abstract][Full Text] [Related]
13. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.
Bhayana S; Booth GL; Asa SL; Kovacs K; Ezzat S
J Clin Endocrinol Metab; 2005 Nov; 90(11):6290-5. PubMed ID: 16118335
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
[TBL] [Abstract][Full Text] [Related]
15. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
Losa M; Garbin E; Pedone E; Mortini P
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
[TBL] [Abstract][Full Text] [Related]
16. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
18. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
19. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
Gatto F; Feelders RA; van der Pas R; Kros JM; Waaijers M; Sprij-Mooij D; Neggers SJ; van der Lelij AJ; Minuto F; Lamberts SW; de Herder WW; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2013 Jan; 98(1):E66-71. PubMed ID: 23118420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
